Numerous cancers have been identified the overexpression of IGF2BP3 including lung cancer (Findeis-Hosey and Xu, 2012), breast cancer (Scott et al., 2018), colorectal cancer (Wei et al., 2017; Xu et al., 2019), hepatocellular carcinoma (Shaalan et al., 2018), pancreatic cancer (Chen et al., 2019), glioblastoma and ovarian clear cell carcinoma (Bi et al., 2016; Dutoit et al., 2018). This evidence concerns the gene IGF2BP3 and breast carcinoma.